Prognostic features and survival of hepatocellular carcinoma in Italy

Lerose, R.; Molinari, R; Rocchi, Emilio; Manenti, F.; Villa, Erica

doi:10.1016/s0959-8049(00)00354-3

Cited by 61 publications

(52 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Follow-up of our HCC patients for 1 year revealed that the overall 1-year mortality was 86% with a median survival time of 8 months. Altekruse et al [19] reported a median survival of < 5 months although a study in Italy found median survival in an untreated group as 10 months, [20] this could be explained by the fact that the majority of HCC patients had more advanced liver disease.…”

Section: Discussionmentioning

confidence: 99%

Association of serum levels of epidermal growth factor with disease severity in patients with unresectable hepatocellular carcinoma

Kohla¹,

Al-Haddad²,

Nada³

et al. 2015

Hepatoma Res

View full text Add to dashboard Cite

Aim: Epidermal growth factor (EGF) is a mitogen for hepatocyte grown in vitro, and its expression is up-regulated during liver regeneration. EGF also plays an important role in tumor initiation and progression. The goal of this study is to assess whether EGF is associated with advanced hepatocellular carcinoma (HCC) and also whether it is a predictive factor of shortened survival. Methods: Serum EGF levels were evaluated in a total of 151 subjects: 51 patients with unresectable HCC, (21 of them were eligible for transarterial chemoembolization (TACE) and serum EGF levels were measured before and 1 week after TACE), 40 patients with chronic hepatitis without cirrhosis, 40 patients with cirrhosis, and 20 healthy controls. Patient demographic and laboratory variables were evaluated as predictive factors of survival in a Cox regression multivariate analysis using SPSS software. Results: The mean serum level of EGF in patients with HCC was 784.49 pg/mL, which was significantly higher (P < 0.05) than all other groups. Mean EGF level in cirrhotic patients was 144.69 pg/mL; in those with chronic hepatitis C without cirrhosis, it was 338.64 pg/mL; and in healthy controls, it was 297.15 pg/mL. In group Ia patients who underwent TACE, the mean serum level of EGF was 759.76 ± 287.88 pg/mL before TACE, and 801.14 ± 276.12 pg/mL 1 week after treatment (P = 0.34). On multivariate Cox regression analysis only age (P = 0.03) and higher serum EGF level (P = 0.005), were inversely correlated with overall survival. Conclusion: EGF levels were found to be significantly higher in HCC patients and together with age were the only predictors of poor survival in these patients. There was an increase in EGF levels 1 week after TACE in response to hypoxia; however, this increase was not statistically significant.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of serum levels of epidermal growth factor with disease severity in patients with unresectable hepatocellular carcinoma

Kohla¹,

Al-Haddad²,

Nada³

et al. 2015

Hepatoma Res

View full text Add to dashboard Cite

show abstract

“…0.0001). GGTP [16][17][18][19] and ALKP levels [20][21][22][23][24] have previously been reported to have prognostic significance in HCC patients. Thus, for the same size grouping (tercile I), the patients with higher AFP had increased levels of GGTP, ALKP, and total bilirubin, and lower serum albumin levels, showing worse liver function with high AFP and thus putatively a more aggressive HCC phenotype, reflected in their worse survival.…”

Section: Discussionmentioning

confidence: 99%

Thrombocytopenia in Relation to Tumor Size in Patients with Hepatocellular Carcinoma

2012

View full text Add to dashboard Cite

show abstract

“…Clinical findings demonstrated that the degree of differentiation of HCC tissues positively correlated with patient survival (12). More recently, analyses of gene expression profiles in HCCs (13) and peritumoral cirrhotic liver tissues (14) provided molecular confirmation of these histological observations, linking expression patterns indicative of fetal and dedifferentiated status with poor patient prognosis.…”

Section: Introductionmentioning

confidence: 91%

Splicing regulator SLU7 is essential for maintaining liver homeostasis

Elizalde¹,

Urtasun²,

Azkona³

et al. 2014

J. Clin. Invest.

128

View full text Add to dashboard Cite

A precise equilibrium between cellular differentiation and proliferation is fundamental for tissue homeostasis. Maintaining this balance is particularly important for the liver, a highly differentiated organ with systemic metabolic functions that is endowed with unparalleled regenerative potential. Carcinogenesis in the liver develops as the result of hepatocellular de-differentiation and uncontrolled proliferation. Here, we identified SLU7, which encodes a pre-mRNA splicing regulator that is inhibited in hepatocarcinoma, as a pivotal gene for hepatocellular homeostasis. SLU7 knockdown in human liver cells and mouse liver resulted in profound changes in pre-mRNA splicing and gene expression, leading to impaired glucose and lipid metabolism, refractoriness to key metabolic hormones, and reversion to a fetal-like gene expression pattern. Additionally, loss of SLU7 also increased hepatocellular proliferation and induced a switch to a tumor-like glycolytic phenotype. Slu7 governed the splicing and/or expression of multiple genes essential for hepatocellular differentiation, including serine/arginine-rich splicing factor 3 (Srsf3) and hepatocyte nuclear factor 4α (Hnf4α), and was critical for cAMP-regulated gene transcription. Together, out data indicate that SLU7 is central regulator of hepatocyte identity and quiescence.

show abstract

Prognostic features and survival of hepatocellular carcinoma in Italy

Cited by 61 publications

References 21 publications

Association of serum levels of epidermal growth factor with disease severity in patients with unresectable hepatocellular carcinoma

Association of serum levels of epidermal growth factor with disease severity in patients with unresectable hepatocellular carcinoma

Thrombocytopenia in Relation to Tumor Size in Patients with Hepatocellular Carcinoma

Splicing regulator SLU7 is essential for maintaining liver homeostasis

Contact Info

Product

Resources

About